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Background: Adiponectin is able to induce NO-dependent vasodilation in Zucker lean (ZL) rats, but this effect is
clearly alleviated in their diabetic littermates, the Zucker diabetic fatty (ZDF) rats. ZDF rats also exhibit
hypoadiponectinemia and a suppressed expression of APPL1, an adaptor protein of the adiponectin receptors, in
mesenteric resistance arteries. Whether an antidiabetic treatment can restore the vasodilatory effect of adiponectin
and improve endothelial function in diabetes mellitus type 2 is not known.
Methods: During our animal experiment from week 11 to 22 in each case seven ZDF rats received an antidiabetic
treatment with either insulin (ZDF+I) or metformin (ZDF+M). Six normoglycemic ZL and six untreated ZDF rats
served as controls. Blood glucose was measured at least weekly and serum adiponectin levels were quantified via
ELISA in week 11 and 22. The direct vasodilatory response of their isolated mesenteric resistance arteries to
adiponectin as well as the endothelium-dependent and -independent function was evaluated in a small vessel
myograph. Additionally, the expression of different components of the adiponectin signaling pathway in the
resistance arteries was quantified by real-time RT-PCR.
Results: In ZDF rats a sufficient blood glucose control could only be reached by treatment with insulin, but both
treatments restored the serum levels of adiponectin and the expression of APPL1 in small resistance arteries.
Nevertheless, both therapies were not able to improve the vasodilatory response to adiponectin as well as
endothelial function in ZDF rats. Concurrently, a downregulation of the adiponectin receptors 1 and 2 as well as
endothelial NO-synthase expression was detected in insulin-treated ZDF rats. Metformin-treated ZDF rats showed a
reduced expression of adiponectin receptor 2.
Conclusions: An antidiabetic treatment with either insulin or metformin in ZDF rats inhibits the development of
hypoadiponectinemia and downregulation of APPL1 in mesenteric resistance arteries, but is not able to improve
adiponectin induced vasodilation and endothelial dysfunction. This is possibly due to alterations in the expression
of adiponectin receptors and eNOS.
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Adiponectin is a 30-kDa adipokine, which is predomi-
nantly and abundantly secreted form adipose tissue
[1-3]. Unlike serum levels of other adipokines, levels of
adiponectin characteristically correlate negatively with
obesity and its comorbidities [2,4-6]. Therefore hypoadi-
ponectinemia serves as a marker of adipose tissue dys-
function and the metabolic syndrome [7,8]. Adiponectin
exerts insulin-sensitizing and antiinflammatory actions
in liver and muscle cells [9,10] and has vasoprotective
effects [11-13]. Adiponectin binds at the cellular le-
vel to two specific transmembrane receptors, adiponec-
tin receptor 1 (AdipoR1) and adiponectin receptor 2
(AdipoR2) [14,15], which provokes an intracellular ac-
tivation of the 5`-AMP-activated protein kinase (AMPK)
and PPAR-alpha [16]. APPL1 (adaptor protein, phospho-
tyrosine interaction, PH domain and leucine zipper
containing 1) is the first described adaptor protein for
the adiponectin receptors [17] and seems to play an im-
portant role in the intracellular signal transmission from
the receptors to AMPK and PPAR-alpha as well as in
the crosstalk with the insulin signaling pathway [18-20].
In contrast, its protein isoform, APPL2 (adaptor protein,
phosphotyrosine interaction, PH domain and leucine
zipper containing 2), seems to act as a negative regulator
of adiponectin signaling [21].
In the last years several studies could prove that
adiponectin causes NO production in endothelial cell cul-
tures by binding to its receptors and a consecutive acti-
vation of APPL1, AMPK and endothelial nitric oxidase
(eNOS) [22-25]. Recently, we [26] could show that
adiponectin indeed provokes a NO-dependent vasodila-
tion of mesenteric resistance arteries in nondiabetic
Zucker lean (ZL) rats. Additionally, this vasodilation was
diminished in their diabetic littermates, the Zucker dia-
betic fatty (ZDF) rat, which also exhibited endothelial dys-
function. As possible pathological mechanism we found
hypoadiponectinemia in ZDF rats and a downregulation
of APPL1 in their mesenteric arteries at mRNA level. For
this reason, we concluded that a decreased adiponectin
signaling through hypoadiponectinemia and a reduced
sensitivity to adiponectin is at least in part responsible for
endothelial dysfunction in diabetes mellitus type 2. This
hypothesis was supported by other studies demonstrating
endothelial dysfunction in hypoadiponectinemia and an
improvement of endothelial function by replenishment of
adiponectin levels [27-29].
In this study we wanted to test, whether an anti-
diabetic treatment with either insulin or metformin can
improve endothelial dysfunction and restore vasorelaxa-
tion to adiponectin in ZDF rats. Further, we wanted to
detect effects on the expression levels of adiponectin re-
ceptors, APPL1, APPL2 and endothelial nitric oxidase
(eNOS) via real-time RT-PCR.Methods
Animal experiments
The study was approved by the local committee on ani-
mal research and is in accordance with the “Guide for
the Care and Use of Laboratory Animals” published by
the US National Institutes of Health. Six male Zucker
lean (ZL) rats (fa/-) and twenty male Zucker diabetic
fatty (ZDF) rats (fa/fa) were studied from an age of 11
weeks until an age of 22 weeks. Of the ZDF rats, six
were kept as untreated controls throughout the whole
experiment, seven were treated with insulin subcuta-
neously (ZDF+I) and the remaining seven animals were
treated with metformin solved in tap water (ZDF+M). In
the insulin group blood glucose was measured every sec-
ond day after 6 hours fasting (ACCU-CHEK Sensor,
Roche GmbH, Mannheim, Germany). Treatment target
was to reach nearly normal blood glucose levels. There-
fore the insulin dose was adjusted to the last blood glu-
cose value prior to the planned insulin administration.
Blood glucose in the metformin group was quantified
twice a week and metformin dose was increased from
initially 300 up to 600 mg/kg/day as the maximum tole-
rable concentration without severe toxic side effects for
rats [30]. Blood glucose in untreated ZDF and ZL rats
was measured weekly. Animals were individually housed
on a 12-hour dark/12-hour light cycle. They were fed a
Purina 5008 rat chow containing 23% protein, 6.5% fat,
58.5% carbohydrates, 4% fiber and 8% ash. Rats received
tap water ad libitum. At baseline (week 11) and in the
last week (week 22) serum levels of adiponectin were
measured (B-Bridge International, Inc., Mountain View,
USA) via ELISA according to the instructions of the
manufacturer. Systolic blood pressure as well as heart
rate was assessed every two weeks by tail cuff method
using an automated cuff inflator-pulse detection system
(CODA2 Multi-Channel, Computerized, EMKA TECH-
NOLOGIES, Paris, France). Body weight was measured
weekly. At the end of the experiment animals were
sacrificed and the mesenteric vasculature was dissected
for preparation of small resistance arteries.
Preparation and study of small resistance arteries
As described previously [26], a third-order branch from
the mesenteric artery of the different investigated rats was
prepared and mounted on a pressure myopraph (DMT,
Aarhus, Danmark). First, the vessels media thickness and
the lumen diameters were measured. Then, after precon-
traction with norepinephrine (10-5 mol/L), endothelium-
dependent and independent relaxation was assessed with
acetylcholine (ACh) (10-9-10-4 mol/L) and sodium nitro-
prusside (SNP) (10-5-10-2 mol/L), respectively. Also, the
endothelial vasodilator function of adiponectin was quanti-
fied after precontraction with norepinephrine (10-5 mol/L)
by a stepwise administration of globular adiponectin in
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(AXXORA GmbH, Lörrach, Germany). The NO-
dependency of the observed vasodilatory response to
adiponectin was tested by an additional preincubation and
application of L-nitroarginine-methyl-ester (L-NAME)
(10-5 mol/L), an inhibitor of the endothelial NO synthase
(eNOS).
In all experiments the vasodilation of the vessels was
calculated as percentage after a maximal precontraction
with 10-5 mol/L norepinephrine using the following for-
mula: vasodilation (%) = (DX-DNE)/(DR-DNE)x100. Thereby
DX is the actual measured diameter at a given concentra-
tion of adiponectin, ACh or SNP. DNE is the diameter
under precontration with norepinephrine, and DR is the
resting diameter of the vessel.
Expression of adiponectin receptors, APPL1, APPL2 and
eNOS
The expression of the adiponectin receptors, AdipoR1 and
AdipoR2, the adaptor proteins, APPL1 and APPL2, as well
as the expression of eNOS in the small arteries was mea-
sured by using a real-time RT-PCR. Therefore, same
calibre branches of the mesenteric artery were collected
and cleaned from adipose and connecting tissue. Total
RNA was extracted using RNeasy kit (Quiagen, Hilden,
Germany) according to the instructions of the manufac-
turer. For first-strand cDNA synthesis, 1 μg total RNA
was reverse transcribed with 1U MMLV Reverse Tran-
scriptase, 1 μg Random Primer, 1 mM deoxynucleotide
triphosphate mixture, 1 μl recombinant RNasinW ribo-
nuclease inhibitor and transcription buffer with 5 mM
MgCl2 in a final volume of 10 μl (all from Promega,
Mannheim, Germany). The reaction mixture was incu-
bated at 37°C for 60 min, followed by heat inactivation of
the enzyme at 95°C for 5 min. After cooling on ice for 5
min, the cDNA was stored at − 20°C. In parallel, 1 μg total
RNA was processed without reverse transcription to con-
trol for contamination with genomic DNA. Real-time
RT-PCR detection of AdipoR1, AdipoR2, APPL1, APPL2
and eNOS was carried out using the AbiPrism 7900 TaqMan
(Applied Biosystems, Foster City; CA, USA). Beta-actin
was used as housekeeping gene for normalization. The
TaqMan probes for AdipoR1, AdipoR2, eNOS, iNOS, and
for beta-actin were purchased from Applied Biosystems
(Foster City, USA). Primers for APPL1 and APPL2 brid-
ging at least one intron were designed and purchased
from MWG-Operon (Ebersberg, Germany) as described
previously [26].
Statistical analysis
From the assessed biometric data, the levels of serum
parameters and the relative mRNA expressions the
means of every measurement for each animal group
were calculated. The groups were compared using one-way ANOVA with Holm-Sidak or Fisher LSD method as
post hoc test. Outliers were detected and excluded with
the Nalimov test. The curves created from the measure-
ments in the small vessel myograph were compared
using two-way ANOVA for repeated measurements with
Holm-Sidak method as post hoc test. All data are pre-
sented as means ± SEM. A p-value of <0.05 was consi-
dered to be significant.Results
Biometric data and blood glucose levels of ZL and ZDF
rats
Table 1 shows the biometric data of different animal
groups exemplarily at the beginning and the end of the
experiment. In week 12 ZL rats were significantly lighter
than diabetic ZDF rats. Under the fed high-caloric diet
in the course of the animal experiment ZL rats gained
about 25% of weight and it was equal to untreated and
metformin-treated ZDF rats in the following weeks,
which also showed a slight weight gain during the ex-
periment. In contrast, insulin-treated ZDF rats rapidly
and excessively increased their body weight by about
60% until week 22 due to anabolic effects of insulin.
Consecutively, their weight was significantly higher than
in the other animal groups at the end of the experiment.
Considering the systolic blood pressure, significant dif-
ferences could be detected only in week 12 with a higher
blood pressure in ZL in comparison to ZDF rats. In the
following weeks the blood pressure equalized between
the groups. During the whole experiment heart rate was
significantly higher in ZL rats than in untreated and
metformin-treated ZDF rats. Insulin-treated ZDF rats
showed higher heart rates in comparison to the other
diabetic animal groups only in week 12.
Table 1 also depicts blood glucose levels in week 11
and 22. As expected, ZDF rats exhibited already at an
age of 12 weeks significantly elevated blood glucose
levels in terms of diabetes mellitus type 2. In contrast,
ZL rats had normal blood glucose during the experi-
ment. Concurrently, it got obvious that treatment with
metformin even in highest tolerable doses had no rele-
vant effect on blood glucose levels. Only treatment with
insulin could decrease blood glucose to normal levels
even though they were still slightly higher than in ZL
rats. Adiponectin serum levels were similar at the begin-
ning of the experiment (ZL 4.1 ± 0.1 μg/ml; ZDF 3.8 ±
0.4 μg/ml; ZDF+I 4.0 ± 0.5 μg/ml; ZDF+M 4.2 ± 0.3 μg/ml.
p = 0.929). In the next weeks adiponectin levels decreased
only in untreated ZDF rats, while they were stable in
nondiabetic ZL rats and insulin- as well as metformin-
treated ZDF rats. This resulted in a significant hypoadipo-
nectinemia of ZDF rats in comparison to all other animal
groups in week 22 (Figure 1).
Table 1 Biometric data and blood glucose levels
Parameters
ZL ZDF ZDF+I ZDF+M
p
(n = 6) (n = 6) (n = 7) (n = 7)
Body Weight at Week 12 [g] 333 ± 10* 367 ± 11 376 ± 6 377 ± 10 0.001
Body Weight at Week 22 [g] 415 ± 14 410 ± 15 603 ± 10† 425 ± 14 0.001
SBP at Week 12 [mmHg] 151 ± 6§ 118 ± 3 128 ± 5 125 ± 6 0.002
SBP at Week 22 [mmHg] 137 ± 6 129 ± 7 125 ± 3 136 ± 2 0.425
Heart Rate at Week 12 [bpm] 595 ± 16# 471 ± 26 543 ± 12¥ 475 ± 18 0.001
Heart Rate at Week 22 [bpm] 549 ± 14⍑ 460 ± 17 489 ± 12 465 ± 23 0.023
Blood Glucose at Week 11 [mg/dl] 77 ± 4~ 245 ± 15 239 ± 8 226 ± 9 <0.001
Blood Glucose at Week 22 [mg/dl] 75 ± 3Φ 259 ± 17 106 ± 10¶ 231 ± 24 <0.001
Abbreviations: ZL Zucker lean rats, ZDF Zucker diabetic fatty rats, ZDF+I Zucker diabetic fatty rats treated with insulin, ZDF+M Zucker diabetic fatty rats treated
with metformin, SBP systolic blood pressure. p p-value for one-way ANOVA.
Post hoc testing: * p < 0.001 vs. ZDF, ZDF+I and ZDF+M. † p < 0.001 vs. ZL, ZDF+I and ZDF+M. § p < 0.001 vs. ZDF, p = 0.002 vs. ZDF+M, p = 0.005 vs. ZDF+I. # p <
0.001 vs. ZDF and ZDF+M. ¥ p = 0.011 vs. ZDF, p = 0.009 vs. ZDF+M. ⍑ p = 0.005 vs. ZDF, p = 0.007 vs. ZDF+M. ~ p < 0.001 vs. ZDF, ZDF+I and ZDF+M. Φ p < 0.001
vs. ZDF and ZDF+M. ¶ p < 0.001 vs. ZDF and ZDF+M.
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The vasodilation response of small resistance arteries to
adiponectin was tested after precontraction with norepin-
ephrine (Figure 2). We found a dose dependent vasodila-
tory response for adiponectin especially in normoglycemic
ZL rats. Maximum vasodilation was reached at a concen-
tration of 0.5 μg/ml adiponectin with 30 ± 4% in ZL rats.
In contrast, vasodilation in ZDF rats was clearly blunted,
but a slight vasodilation could also be detected with a
maximum vasodilation of 18 ± 2% at highest used concen-
trations of adiponectin. Of notice, treatment with insulin
or metformin did not improve vasodilatory response to
adiponectin in small resistance arteries (maximum vaso-
dilation: ZDF+I 19 ± 3%; ZDF+M 17 ± 3%). Only diffe-
rences between ZL and ZDF rats irrespective of treatment
were statistically significant. To test, whether the observed
vasodilatory response of the small arteries to adiponec-Figure 1 Serum adiponectin levels in week 22. Untreated ZDF
animals show significantly reduced levels of adiponectin, which
are restored by insulin or metformin treatment. One-way ANOVA
p = 0.042. Post hoc testing: * p = 0.040 vs. ZL, p = 0.008 vs. ZDF+I,
p = 0.018 vs. ZDF+M.tin is NO dependent, small arteries were treated with
L-NAME, an inhibitor of eNOS, additionally to adiponec-
tin. Thereby, the initially noted vasodilatory effect of
adiponectin was completely blunted (Figure 3). This indi-
cates that the vasodilatory effect of adiponectin is medi-
ated by NO.
Relaxation response to acetylcholine and sodium
nitroprusside
Endothelial function was assessed by stimulation of small
resistance arteries with ACh after precontraction with nor-
epinephrine (Figure 4). We found a clear dose-dependent
vasodilation with a maximum relaxation of 92 ± 4% for
ZDL rats at a concentration of 10-4 mol/L ACh. This was
diminished in all diabetic animals regardless of treatment,Figure 2 Dose-dependent relaxation of resistance arteries to
cumulative doses of adiponectin after precontraction with
norepinephrine. Adiponectin-induced vasodilation is restricted in
untreated ZDF animals and remains unchanged by insulin or
metformin treatment. Two-way ANOVA for repeated measurements:
* p = 0.002 vs. ZDF and ZDF+I, p = 0.001 vs ZDF+M; # p = 0.002
vs ZDF.
Figure 3 Dose-dependent relaxation of resistance arteries to
cumulative doses of adiponectin with and without L-NAME
after precontraction with norepinephrine exemplary for ZL and
ZDF rats. Adiponectin-induced vasodilation is nearly totally blunted by
L-NAME indicating NO-dependency of vasodilation. Two-way ANOVA
for repeated measurements: * p < 0.001 vs. ZL+L-NAME; # p < 0.001
vs. ZDF+L-NAME.
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imum vasodilation ZDF 47 ± 7%; ZDF+I 58 ± 10%; ZDF+M
43 ± 10%).
Endothelium-independent vasodilation was assessed
by treatment with SNP (data not shown). Again, vaso-
dilation was dose-dependent and tended to be lower in
diabetic rats, but the difference between ZL and un-
treated ZDF rats was not statistically significant.Figure 4 Dose-dependent relaxation of resistance arteries to
cumulative doses of acetylcholine (ACh) after precontraction
with norepinephrine. Acetylcholine-induced vasodilation is
diminished in ZDF animals indicating endothelial dysfunction, which
can´ t be improved by insulin or metformin. Two-way ANOVA for
repeated measurements: * p < 0.001 vs. ZDF, ZDF+I and ZDF+M;
# p = 0.004 vs. ZDF.Expression of adiponectin receptors, APPL1, APPL2, and
eNOS in mesenteric resistance arteries
The expression of different essential components of the
adiponectin signaling pathway was measured in the
mesenterial arteries by real-time RT-PCR to reveal pos-
sible causes of a different vasorelaxation response to
adiponectin. Thus we performed an expression analysis
for the adiponectin receptors (AdipoR1 and AdipoR2),
the adiponectin receptor adaptor proteins (APPL1 and
APPL2), and eNOS.
We found that AdipoR1 (Figure 5a) is expressed in a
similar amount in ZL and ZDF rats. Insulin provoked a
significant decrease in AdipoR1 expression in compari-
son to untreated ZDF rats, while in metformin-treated
animals AdipoR1 expression remained unchanged. Like-
wise, the expression of AdipoR2 (Figure 5b) was similar
in ZL and ZDF rats, but treatment with either insulin or
metformin caused a significant decrease. Overall APPL1
expression (Figure 6) was lowest in untreated ZDF rats.
Its expression was significantly increased by metformin
and insulin. Also, in ZL rats APPL1 expression was sig-
nificantly higher than in untreated ZDF rats. However,
no significant differences could be detected for the
expression of APPL2. Its expression was highest in
insulin-treated (ZDF+I 1.1 ± 0.12) and lowest in un-
treated and metformin-treated ZDF rats (ZDF 0.89 ±
0.05; ZDF+M 0.79 ± 0.05), but the differences in both
cases did barely not reach the significance level (p = 0.09
vs. ZDF; p = 0.057 vs. ZDF+M).
eNOS expression in small resistance arteries (Figure 7)
was similar high in ZL and untreated ZDF rats. Treat-
ment with insulin significantly decreased the expression
of eNOS, while treatment with metformin did not affect
the expression of eNOS.
Discussion
The major findings of our present study are: (1) an
antidiabetic treatment with insulin or metformin inhibits
the development of hypoadiponectinemia and downre-
gulation of APPL1 in ZDF rats, but (2) both treatments
are not able to improve adiponectin-induced vasodila-
tion and endothelial dysfunction; (3) treatment with in-
sulin is able to control blood glucose levels in ZDF rats,
but (4) causes a decrease of AdipoR1, AdipoR2 and
eNOS expression in small mesenteric resistance arteries;
(5) treatment with metformin even in highest tolerable
doses does not decrease blood glucose levels in ZDF rats
and (6) reduces expression of AdipoR2 in mesenteric
arteries.
Effect of antidiabetic treatment on adiponectin-induced
vasodilation and endothelial function
In our recent study [26] we found that adiponectin
provokes a NO-dependent vasodilation of mesenterial
Figure 5 Relative mRNA-expression of adiponectin receptors in small resistance arteries. a) Expression of AdipoR1. Insulin causes a
significant downregulation of AdipoR1 expression. One-Way ANOVA p = 0.024. Post hoc testing: * p = 0.007 vs. ZL, p = 0.008 vs. ZDF+M b)
Expression of AdipoR2. Insulin or metformin treatment causes a significant downregulation of AdipoR2 expression. One-way ANOVA p < 0.001.
Post hoc testing: * p = 0.006 vs. ZDF+I, p < 0.001 vs. ZDF+M; # p = 0.005 vs. ZDF+I, p < 0.001 vs. ZDF+M.
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arteries of ZDF rats. The expression analysis of different
components of the adiponectin signaling pathway
showed a significant downregulation of APPL1 in mes-
enteric arteries of ZDF rats. In addition ZDF rats exhi-
bited hypoadiponectinemia and endothelial dysfunction.
Therefore, we concluded that hypoadiponectinemia itself
and a reduced intracellular adiponectin signaling are
partly responsible for endothelial dysfunction in diabetes
mellitus type 2. This hypothesis was supported by a
study of Ouchi et al. [29], who found that adiponectin-
knockout mice exhibit endothelial dysfunction and an-
other study of Cao et al. [27], in which a replenishment
of adiponectin in knock-out mice normalized endothelial
function. Similar Deng et al. [28] could show thatFigure 6 Relative mRNA-expression of APPL1 in small
resistance arteries. APPL1 expression is significantly reduced in
untreated ZDF animals and expression levels are restored by insulin
or metformin treatment. One-way ANOVA p = 0.03. Post hoc testing:
* p = 0.028 vs. ZL, p = 0.044 vs. ZDF+I, p = 0.017 vs. ZDF+M.endothelial dysfunction in high-fat diet fed rats was
ameliorated by an in vitro incubation of aortic rings with
globular adiponectin in high doses. Therefore interven-
tions directed to increase adiponectin levels in diabetes
mellitus type 2 are possibly able to improve endothelial
function. Against our expectations in the present study
an antidiabetic treatment with insulin or metformin could
not improve the vasodilatory effect of adiponectin and
endothelial function in diabetic ZDF rats (Figure 2+4),
although both restored adiponectin levels and also in-
creased the expression of APPL1 in ZDF rats to levels of
nondiabetic ZL rats (Figure 1+6). Thereby, it has to be
mentioned that these results of course only apply to our
ex vivo setting and that we can`t make a statement
to possible in vivo effects of the tested antidiabetic
treatment.Figure 7 Relative mRNA-expression of eNOS in small resistance
arteries. Insulin causes a significant downregulation of eNOS
expression. One-way ANOVA p = 0.047. Post hoc testing: * p = 0.048
vs. ZL, p = 0.01 vs. ZDF, p = 0.016 vs. ZDF+M.
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observed downregulation of both adiponectin receptors
(Figure 5) and eNOS (Figure 7), which with their loca-
lization at the beginning and end of the adiponectin sig-
naling pathway are the main regulators of adiponectin
sensitivity and NO-production. Therefore, the reduced
expression of the adiponectin receptors and eNOS might
diminish the benefical effects of increased adiponectin
serum and APPL1 expression levels. Additionally, the in-
crease of APPL1 expression might be counteracted by the
complementary increase of APPL2 expression, even if not
statistically significant. The fact that an early treatment
with insulin in diabetes mellitus type 2 does not improve
endothelial function is in line with a recent study in
human, in which flow-mediated dilation remained un-
changed after initiation of insulin therapy [31].
For metformin-treated animals our study suggests two
possible reasons for the absent improvement of vaso-
dilation. On the one hand the reduced expression of
AdipoR2 (Figure 5b) and on the other hand the uncon-
trolled blood glucose levels. Thereby, decreased expres-
sion of AdipoR2 may at least in part reduce adiponectin
sensitivity resulting in decreased eNOS activation and
NO production. The fact that metformin is not able to
control blood glucose in ZDF rats was already observed
in another study, since ZDF rats develop insulin defi-
ciency between an age of 14 and 21 weeks [32]. An un-
controlled diabetes mellitus may cause endothelial
dysfunction through additional mechanisms apart from
adiponectin signaling. Accordingly, a study in another
rat model of diabetes mellitus type 2 showed an im-
provement of endothelial function in aortic rings after
metformin therapy, but this effect was associated with a
significant improvement of blood glucose levels [33].
However, in another experiment metformin therapy
improved endothelial function independent of a blood
glucose lowering effect, but this study was performed in
streptozotocin-induced diabetic rats, a model of diabetes
mellitus type 1 [34].
Effect of antidiabetic treatment on adiponectin levels and
expression of components of the adiponectin signaling
pathway
As mentioned above, both antidiabetic treatments inhi-
bited the development of hypoadiponectinemia during
the animal experiment (Figure 1).
Generally, the effect of insulin on adiponectin serum
levels is contentious. In vitro, insulin inhibits the expres-
sion of adiponectin at mRNA level [35], but then it leads
to an increased adiponectin secretion from adipocytes
[36,37]. In vivo, there is a good documented association
of hypoadiponectinemia with insulin resistance and dia-
betes mellitus type 2 [38], but the effect of insulin thera-
py on serum levels of adiponectin is not well studied sofar. A study in five healthy male volunteers showed a
decrease of adiponectin levels during a hyperinsulinemic
euglycemic clamp [39]. Another study with insulin treat-
ment in a murine model of obesity and diabetes mellitus
type 2, the db/db mice, suggested no impact on adipo-
nectin levels [40]. A recent study indicates an elevation
of adiponectin levels in a hyperinsulinemia rat model
[41]. In this respect, our study supports new evidence
for a positive effect of insulin therapy on adiponectin
levels despite of an increase in body weight.
For the effect of metformin on adiponectin levels there
are more studies available. In vitro metformin increased
the expression and secretion of adiponectin in human
adipose tissue samples [42]. However, results of studies
in humans with metformin treatment for different diseases
showed mostly no effect on adiponectin serum levels
[43-48], but it also exists evidence for an adiponectin-
raising effect [49-51]. In this context our animal study
supports a benefical effect of metformin on adiponectin
levels.
Considering the adiponectin receptors, we found un-
der insulin treatment a significantly decreased expres-
sion of AdipoR1 and AdipoR2 compared to untreated
animals (Figure 5). On this so far data from an in vitro
study exist showing a reduced expression of both
adiponectin receptors in skeletal and vascular smooth
muscle cells by insulin [52]. Another recent study also
revealed that an insulin infusion in a rat model de-
creased expression of AdipoR1 in skeletal and myocar-
dial muscle [41]. This effect seems to be mediated by a
direct repressive effect of insulin on the promoter acti-
vity of AdipoR1 [53]. Our data match these studies and
further support and expand these findings to the vascu-
lature. The effect of metformin on adiponectin receptor
expression was so far studied in adipose tissue, skeletal
muscle and liver of ZDF rats [32]. In this experiment a
significant increase for both receptors in skeletal muscle
was detected and our study now expands these findings
with expression data for small mesenteric resistance ar-
teries showing a decreased expression of AdipoR2.
To our knowledge, with the present study we provide
first data on the effect of an antidiabetic treatment on
the expression of APPL1 and APPL2 showing that insu-
lin as well as metformin is able to increase the expres-
sion of APPL1 in resistance arteries of ZDF rats, while
APPL2 expression remained unchanged (Figure 6).
In respect to eNOS, we found that insulin treatment
significantly reduced its expression in mesenteric arteries
(Figure 7). This goes with findings of Zanetti et al., who
showed that an overexpression of eNOS in diabetic ani-
mal model can be attenuated by insulin treatment [54].
However, another study in ZDF rats found no effect of
an insulin therapy on eNOS expression in the aorta [55].
Metformin treatment did not alter eNOS expression in
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animal models of diabetes mellitus [56].
However, our expression analyses are performed with
real-time RT-PCR and therefore only reflect expression
at mRNA level, since second order mesenteric arteries
of rats do not yield enough protein for a reliable western
blot analysis.
Conclusion
ZDF rats as a model of diabetes mellitus type 2 are cha-
racterized by hypoadiponectinemia, a reduced expression
of APPL1 and a decreased response of their mesenteric
arteries to adiponectin and acetylcholine in terms of endo-
thelial dysfunction. In our present study, we explored the
effect of an antidiabetic treatment with insulin or metfor-
min on their endothelial function and the expression of
different components of the adiponectin signaling path-
way. We found that both treatments restored adiponectin
serum levels and expression of APPL1 in small mesenteric
resistance arteries, but were not able to improve endothe-
lial function. This is possibly due to a reduced expression
of AdipoR1, AdipoR2 and eNOS under insulin treatment
and a reduced expression of AdipoR2 and uncontrolled
blood glucose under metformin therapy in our animal
model. Since the phenotype of type 2 diabetes mellitus in
the ZDF animal model is based on a homozygous muta-
tion in the leptin receptor, our results can only be applied
with restrictions to humans. In addition, it can't be ex-
cluded that our results are at least in part influenced by
the genetic difference between ZL and ZDF rats.
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